Effect of 4-Month Intermittent Atropine Penalization in Amblyopic Children for Whom Patch Therapy Had Failed

Seol, Bo Ram; Yu, Young Suk; Kim, Seong Joon

doi:10.3928/01913913-20170329-02

Cited by 7 publications

(3 citation statements)

References 19 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Repka et al [ 22 ] compared daily atropine to weekend atropine treatment for 168 children younger than 7 years with moderate amblyopia. In short, daily and weekend atropine treatment provided similar visual acuity improvement.…”

Section: Classical Treatmentsmentioning

confidence: 99%

Current Management of Amblyopia with New Technologies for Binocular Treatment

Boniquet-Sanchez

Sabater-Cruz

2021

Vision

View full text Add to dashboard Cite

Amblyopia is the most common cause of monocular poor vision affecting up to 3.7% of the global population. Classically, the first step in treatment has been optical correction, followed by patching and/or pharmacological treatment. However, this is an evolving scenario, since researchers and clinicians are interested in new binocular treatments due to the increasing development of new technologies. In this article main, current binocular treatments as Dig Rush, falling blocks, I-BiT, Occlu-tab, Vivid Vision, and movies are reviewed for binocular amblyopia management.

show abstract

Section: Classical Treatmentsmentioning

confidence: 99%

Current Management of Amblyopia with New Technologies for Binocular Treatment

Boniquet-Sanchez

Sabater-Cruz

2021

Vision

View full text Add to dashboard Cite

show abstract

“…A PEDIG study evaluated this increase of patching from 2 to 6 h in children 3-8 years old with stable residual amblyopia, and found that 40% children showed at least 2 lines of VA improvement compared to 18% in the 2 h patching group [109]. Authors have evaluated 4-month intermittent atropine penalization (1% atropine) for children in whom patching therapy had failed [110]. After 4 months of treatment, the intermittent atropine therapy improved VA, and the effect was superior in younger children and who had poorer pre-atropine treatment VA.…”

Section: Residual Amblyopiamentioning

confidence: 99%

Management of amblyopia in pediatric patients: Current insights

Sen

Singh

Saxena

2021

Eye

View full text Add to dashboard Cite

Amblyopia is a cause of significant ocular morbidity in pediatric population and may lead to visual impairment in future life. It is caused due to formed visual deprivation or abnormal binocular interactions. Several risk factors in pediatric age group may lead to this disease. Author groups have tried managing different types of amblyopia, like anisometropic amblyopia, strabismic amblyopia and combined mechanism amblyopia, with optical correction, occlusion therapy, penalization, binocular therapy and surgery. We review historical and current management strategies of different types of amblyopia affecting children and outcomes in terms of visual acuity, binocularity and ocular deviation, highlighting evidence from recent studies. Literature searches were performed through Pubmed. Risk factors for amblyopia need to be identified in pediatric population as early in life as possible and managed accordingly, as visual outcomes in amblyopia are best if treated at the earliest. Although, monocular therapies like occlusion or penalization have been shown to be quite beneficial over the years, newer concepts related to binocular vision therapy are still evolving.

show abstract

“…13 Additional clinical uses for atropine include cycloplegic refractions and penalization treatment in amblyopia. 13,14 In 1864 Donders described the usefulness of atropine for cycloplegic refractive error determination. He also depicted atropine as a possible treatment of asthenopia and myopic increase associated with spasm of accommodation.…”

Section: Introductionmentioning

confidence: 99%

Use of Atropine to Slow the Progression of Myopia: A Literature Review and Guidelines for Clinical Use

2018

VDR

View full text Add to dashboard Cite

Atropine 1% and various lower concentrations of atropine (0.5-0.01%) have been used to slow the progression of myopia. Cumulative data and meta-analysis from a number of studies have demonstrated that the most effective method for slowing the progression of myopia is atropine 1% instilled daily ( progression is slowed by almost 80%). Atropine’s side effects of mydriasis and cycloplegia have kept it from being prescribed more frequently. Recent studies have demonstrated that lower concentrations of atropine 0.025% to 0.01% are effective with significantly lower side effects. Discontinuing atropine treatment has displayed a rebound of myopia progression with higher amounts of rebound associated with higher atropine concentrations. Ocular side effects of atropine can be effectively managed with photochromic progressive lenses. In summary, atropine is not only safe, but it is also an effective drug to slow the progression of myopia.

show abstract

Effect of 4-Month Intermittent Atropine Penalization in Amblyopic Children for Whom Patch Therapy Had Failed

Cited by 7 publications

References 19 publications

Current Management of Amblyopia with New Technologies for Binocular Treatment

Current Management of Amblyopia with New Technologies for Binocular Treatment

Management of amblyopia in pediatric patients: Current insights

Use of Atropine to Slow the Progression of Myopia: A Literature Review and Guidelines for Clinical Use

Contact Info

Product

Resources

About